Kite And Arcellx Close Agreement To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma

Published on :

SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.

Kite to Add 100 New Jobs in Frederick County With Expansion of Cell Therapy Manufacturing Operations

Published on :

Kite, a Gilead Company, announced plans to expand its global cell therapy supply chain operations in Frederick County, Maryland. This year, the California-based company will begin construction on an approximately 70,000 square-foot centralized raw materials warehouse that will serve Kite’s global manufacturing network and will be located adjacent to its existing facility in the Urbana Corporate Center. The expansion will bring an additional 100 jobs to the area, with the company expecting to employ more than 500 full-time staff between its two facilities by the end of 2026.

Greater Philadelphia Q4 2022 News Recap – December was a Pivotal Month for Cellicon Valley Companies

Published on :

Cellicon Valley companies closed out 2022 with a roar. Madrigal Pharmaceuticals announced a breakthrough in NASH that could result in the first-approved drug for that disease. Galera Therapeutics closed out December with plans to seek approval for its severe oral mucositis therapy.

Kite to Bolster Cell Therapy Capabilities through Acquisition of Carl June’s Tmunity Therapeutics

Published on :

A Gilead Sciences company, Kite announced Tmunity’s next-generation CAR-T therapies and technology will complement its own cell therapy research capabilities. Kite’s acquisition of Tmunity, founded by Carl June, creates a strong bridge between the BioHealth Capital Region, where Kite maintains its manufacturing capabilities in Frederick, and the Greater Philadelphia biohub.

Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer

Kite Pharma Sponsor
Published on :

Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets, platform capabilities, and a strategic research and licensing agreement with the University of Pennsylvania (Penn).

Arcellx And Kite Announce Strategic Collaboration To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma

Published on :

Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma.  Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.

In Conversation: Trushar Agrawal, Senior Director and Head of Manufacturing at Kite Pharma

Published on :

This past summer, Kite promoted biotech industry veteran Trushar Agrawal from his Director of QA role to Senior Director, Head of Manufacturing for the Frederick site. Agrawal will work to bring on new team members as the site ramps up commercial production of its CAR T-cell therapy product, which is used to treat people living with blood cancer. 

Kite Hosts Cell Therapy Hiring Event at Growing Frederick, Maryland Facility

Published on :

The “Onsite at Kite” event, which was held on World Lymphoma Awareness Day, featured networking opportunities, a facility tour, and panel discussion with site leadership, during which job seekers and industry professionals learned about Kite’s patient focus in manufacturing. 

Kite Pharma Invests in Maryland’s Workforce Development Programming

Published on :

Kite’s choice to plant roots in Maryland has been a boon to the economy and the region’s life sciences ecosystem. Kite has committed to building strong partnerships with the local community across an array of key constituencies, including workforce development initiatives at local universities and life sciences support organizations. Kite’s goal is to augment existing workforce development programming and to help the region continue building a thriving life sciences workforce. 

Kite Launches Program to Attract and Hire Veterans

Published on :

Kite’s cell manufacturing facility in Frederick has recently launched what it calls its Veteran Pathways Program. The program is led by veteran hiring program strategist Bre Cameron. Cameron is a Navy veteran with more than a decade of experience in talent acquisition.